

**IN THE CLAIMS:**

Please amend the claims as follows:

A marked-up version of the claims showing the amendments is attached hereto as Exhibit A. Matter that has been deleted from claims 1, 2, 5, 50, and 63 is indicated by brackets and matter that has been added is indicated by underlining.

Cancel claims ~~13-15~~ and ~~19-21~~ without prejudice.

Please amend the claims 1, 2, 5, 50, and 63 to read as follows:

- 
- sub  
B1  
a1
1. (Amended) A method for altering the cell fate otherwise adopted by a cell comprising:
- (a) altering Notch pathway function in the cell by a method comprising contacting the cell *in vitro* with, or administering to an organism comprising the cell, a modulator of Notch pathway function;
  - (b) concurrently with step (a), altering the function of a cell fate control gene pathway in the cell by a method comprising contacting the cell *in vitro* with, or administering to an organism comprising the cell, a modulator of a cell fate control gene pathway function, wherein the cell fate control gene pathway is not the Notch pathway; and
  - (c) subjecting the cell to conditions that allow cell fate determination to occur.
- 
2. (Amended) The method according to claim 1 comprising contacting the cell *in vitro* with the modulator of Notch pathway function.
- 
- a2 5. (Amended) The method according to claim 1 comprising administering to an organism comprising the cell the modulator of Notch pathway function.
- 
- a3 50. (Amended) The method according to claim 1 or 5 wherein the altering of cell fate is a change in tissue or organ type.
-

63. (Amended) The method according to claim 1 wherein the modulator of Notch pathway function and the modulator of the cell fate control gene pathway function are purified.

Please add the following new claims:

70. (New) The method of claim 2, wherein the modulator of Notch pathway function is an antagonist of Notch pathway function.

71. (New) The method of claim 70, which comprises contacting the cell *in vitro* with the modulator of a cell fate control gene pathway function.

72. (New) The method of claim 71, wherein the modulator of the cell fate control gene pathway function is an antagonist of the cell fate control fate control gene pathway function.

73. (New) The method of claim 70, which comprises administering to an organism comprising the cell the modulator of a cell fate control gene pathway function.

74. (New) The method of claim 73, wherein the modulator of the cell fate control gene pathway function is an antagonist of the cell fate control fate control gene pathway function.

75. (New) The method of claim 5, wherein the modulator of Notch pathway function is an antagonist of Notch pathway function.

76. (New) The method of claim 75, which comprises contacting the cell *in vitro* with the modulator of a cell fate control gene pathway function.

77. (New) The method of claim 76, wherein the modulator of the cell fate control gene pathway function is an antagonist of the cell fate control fate control gene pathway function.

78. (New) The method of claim 75, which comprises administering to an organism comprising the cell the modulator of a cell fate control gene pathway function.

79. (New) The method according to claim 70 comprising contacting the cell *in vitro* with an antagonist of Notch pathway function.

80. (New) The method according to claim 72 comprising introducing into the cell one or more nucleic acids encoding an antagonist of Notch pathway function and an antagonist of a cell fate control gene pathway function such that the antagonists are expressed by the cell.

81. (New) The method according to claim 70 wherein the antagonist of Notch pathway function is a dominant-negative Notch mutant.

82. (New) The method according to claim 70 wherein the antagonist is purified.

83. (New) The method according to claim 70 or 75, wherein the altering of cell fate is a change in tissue or organ type.

#### REMARKS

Claims 1-69 were pending in the instant application. Claims 1, 2, 5, 50, and 63 have been amended, and claims 13-15, and 19-21 canceled without prejudice and replaced by new claims 70-83, to more particularly point out and distinctly claim that which Applicants regard as the invention. The amendments to claims 1, 2, 5, 50 and 63 are supported in the specification at p. 19, lines 26-30; p. 20., lines 3-13; and p. 24, lines 33-36.

New claims 70-83 have been added. Support for the new claims can be found in the specification as originally filed, as set forth in the chart below. No new matter is added.

CLAIMS	SUPPORT IN SPECIFICATION
70	p. 25, lines 36-37; p. 33, lines 11-13; p. 38, line 24 to p. 44, line 20